Radiopharma companies merge after one receives surprise FDA rejection — Live Feedhttps://www.live-feeds.com/feed/radiopharma-companies-merge-after-one-receives-surprise-fda-rejectionContinuously updated, source-cited coverage. Telix Pharmaceuticals to acquire ITM for initial US$1.65 billionhttps://www.live-feeds.com/feed/radiopharma-companies-merge-after-one-receives-surprise-fda-rejectionhttps://www.live-feeds.com/feed/radiopharma-companies-merge-after-one-receives-surprise-fda-rejection#u80561Tue, 22 Sep 2026 21:05:21 +0000Telix Pharmaceuticals is acquiring German radiopharmaceutical biotechnology company ITM in a deal valued at an initial US$1.65 billion. The acquisition follows a surprise FDA rejection for one of the companies. While analysts are "extremely bullish" about the move, Telix stock fell 3% as the deal adds 105.8 million shares. The merger positions Telix as a global leader in the radiopharmaceutical sector, expanding its reach into territory currently held by Novartis.Why it mattersRadiopharmaceuticals combine radioactive isotopes with targeting molecules to treat or image specific diseas